Indian drugmaker Dr. Reddy’s Laboratories Ltd announced that it will launch its generic version of Merck’s COVID-19 antiviral pill, molnupiravir, at a price of Rs 35, which is equivalent to less than 50 cents (US $). 0.4693) per capsule, a company spokesperson said.
The total cost for a patient treated with a five-day 40-capsule regimen of the generic – which will be sold under the brand name Molflu – will be 1,400 rupees (US $ 18.77). By comparison, Merck’s pill treatment in the United States costs $ 700.
“Molflu is expected to be available starting early next week in pharmacies across (India), with a focus on states with high COVID-19 cases,” the company spokesman said.
India last week approved the emergency use of molnupiravir along with two vaccines as the country prepares for a possible spike in rapidly spreading omicron coronavirus cases.
The Asian nation reported 37,379 new cases of COVID-19 on Tuesday, its highest number since early September.
In order to turn India into a manufacturing hub, Merck has signed licensing agreements with eight local drug manufacturers, including Dr. Reddy’s, to manufacture and supply generic versions of molnupiravir to more than 100 low- and middle-income countries.
A total of 13 Indian companies will manufacture molnupiravir, the country’s health minister declared last week.
Governments around the world have rushed to buy a similar but more effective antiviral treatment from Pfizer, while Merck’s pill has suffered some setbacks following disappointing trial data.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
